Australian-developed technology using artificial intelligence to rapidly diagnose infectious diseases is set for a laboratory trial at St Vincent's Hospital in Melbourne.
Medical technology firm LBT Innovations has developed the APAS Independence instrument, which automatically analyses and interprets growth on microbiology culture plates, enabling faster and more efficient diagnosis and reporting of infectious diseases.
The product will be trialled at St Vincent's Hospital from September, and LBT said it will then be trialled in in other laboratories around the world.
"We look forward to seeing the independent results of APAS Independence used in a clinical laboratory setting for the first time as part of our global commercialisation milestones," LBT chief executive Brent Barnes said.
"This is a precursor to selling product in Australia and globally which we still expect to occur at the very end of 2017."
APAS Independence has already been approved by US and Australian regulators, and LBT says tests have shown it to be more accurate than reviews of culture plates by individual microbiologists.
Shares in LBT were up half a cent at 25 cents at 1120 AEST.
Share
